What is Sangui Biotech International Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sangui Biotech International Enterprise Value Chart
Competitive Comparison of Sangui Biotech International's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sangui Biotech International's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Sangui Biotech International's Enterprise Value falls into.
Sangui Biotech International Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sangui Biotech International (OTCPK:SGBI) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Sangui Biotech International's EV-to-EBIT for today is
Sangui Biotech International's current Enterprise Value is $1.14 Mil.
Sangui Biotech International's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Sangui Biotech International's EV-to-EBITDA for today is:
Sangui Biotech International's current Enterprise Value is $1.14 Mil.
Sangui Biotech International's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.
Sangui Biotech International's current Enterprise Value is $1.14 Mil.
Sangui Biotech International's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sangui Biotech International Enterprise Value Related Terms
Thank you for viewing the detailed overview of Sangui Biotech International's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Sangui Biotech International (Sangui Biotech International) Business Description
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGBI has been successfully added to your 